<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687815</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12020541</org_study_id>
    <secondary_id>U01HL119952</secondary_id>
    <nct_id>NCT02687815</nct_id>
  </id_info>
  <brief_title>Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)</brief_title>
  <official_title>Vitamin D to Prevent Severe Asthma Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Celedon, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmavite LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether vitamin D3 prevents severe asthma attacks in children who&#xD;
      have a serum vitamin D (25(OH)D) level &lt;30 ng/ml and who are being treated with inhaled&#xD;
      corticosteroids for asthma. Half the participants will receive vitamin D3 at a dose of 4,000&#xD;
      IU/day, and the other half will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results from experimental studies, observational studies, two small trials, and a recent&#xD;
      meta-analysis suggest that vitamin D reduces the risk of severe asthma exacerbations, and&#xD;
      that this protective effect may be due to immune modulation of viral illnesses and/or&#xD;
      increased response to inhaled corticosteroids (ICS).&#xD;
&#xD;
      On the basis of those findings, the investigators hypothesize that vitamin D reduces the&#xD;
      incidence of severe asthma exacerbations in high-risk school-aged children who have a serum&#xD;
      vitamin D level &lt;30 ng/ml and who are being treated with ICS for persistent asthma. The&#xD;
      investigators further hypothesize that this protective effect results from reduced incidence&#xD;
      of common viral illnesses or enhanced response to ICS. These hypotheses will be tested in a&#xD;
      48-week randomized double-masked placebo-controlled trial of vitamin D3 supplementation to&#xD;
      prevent severe asthma exacerbations in 400 children aged 6 to 16 years who have vitamin D&#xD;
      insufficiency or deficiency (a serum 25(OH)D &lt;30 ng/ml) and experienced a severe exacerbation&#xD;
      in the prior year (a marker of high risk for subsequent events), and who (after a run-in&#xD;
      period) are well controlled on medium-dose inhaled corticosteroids.&#xD;
&#xD;
      Our primary aim will determine whether vitamin D3 (4,000 IU/day) reduces the risk of severe&#xD;
      asthma exacerbations (our primary outcome) in participating children. Secondary aims will&#xD;
      determine the efficacy of vitamin D3 supplementation in: 1) preventing severe asthma&#xD;
      exacerbations due to viral infections, 2) reducing the daily and average cumulative dose of&#xD;
      inhaled corticosteroids.&#xD;
&#xD;
      Study participation involves 8-9 visits, with each visit lasting between 30-90 minutes.&#xD;
      Participation requires completion of study questionnaires, spirometry (breathing tests), and&#xD;
      collection of blood samples (to measure vitamin D levels) and urine samples (to measure&#xD;
      urinary calcium/creatinine ratios) at some study visits. Since the start of the study,&#xD;
      vitamin D levels and urinary calcium/creatinine ratios have been simultaneously measured, to&#xD;
      monitor for both vitamin D toxicity and high risk of severe vitamin D deficiency or rickets,&#xD;
      which (should they occur) would be managed by a pediatric endocrinologist or a pediatric&#xD;
      nephrologist, as appropriate.&#xD;
&#xD;
      All safety data for the study is regularly reviewed by a Data Safety Monitoring Board&#xD;
      appointed by the National Heart, Lung and Blood Institute, as well as by the Institutional&#xD;
      Review Board of each participating institution. Total study participation will last about one&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility of vitamin D supplementation based on protocol threshold: &lt;30% conditional power to&#xD;
    detect pre-specified effect- 16% reduction in severe exacerbations.&#xD;
  </why_stopped>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to a Severe Asthma Exacerbation</measure>
    <time_frame>48 weeks</time_frame>
    <description>A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to Viral-induced Severe Exacerbation</measure>
    <time_frame>48 weeks</time_frame>
    <description>A severe viral asthma exacerbation is defined as a severe asthma exacerbation [defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids] along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants in Whom Fluticasone Dose Was Halved at Visit 6</measure>
    <time_frame>24 weeks</time_frame>
    <description>In the absence of moderate or severe asthma exacerbations, participants may have their dose of inhaled corticosteroids (ICS) reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):&#xD;
Asthma Control Test (ACT) score greater than 19&#xD;
Both pre-bronchodilator FEV1 and FEV1/FVC ≥80% of predicted&#xD;
Use of ≤4 puffs of a rescue inhaler per week&#xD;
≤1 day per month with asthma symptoms preventing full participation in usual daily activities&#xD;
Clinician's judgment regarding adequate asthma control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Cumulative Prescribed Dose of ICS at the End of the Trial</measure>
    <time_frame>48 weeks</time_frame>
    <description>The average cumulative dose of inhaled corticosteroids (ICS) during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo formulations will be in gel cap form and identical to the active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3 4000 IU</intervention_name>
    <description>The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
    <arm_group_label>vitamin D3</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6 to 16 years old&#xD;
&#xD;
          -  Physician-diagnosed asthma for at least one year&#xD;
&#xD;
          -  At least one severe asthma exacerbation in the previous year&#xD;
&#xD;
          -  Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor]&#xD;
             or inhaled β2-agonist [at least three days per week]) for at least six months in the&#xD;
             previous year&#xD;
&#xD;
          -  Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level &lt;30 ng/ml (75 nmol/L))&#xD;
&#xD;
          -  FEV1 ≥70 % of predicted&#xD;
&#xD;
          -  Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after&#xD;
             inhaled short acting beta agonist or increased airway responsiveness to methacholine&#xD;
             (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)&#xD;
&#xD;
          -  Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma&#xD;
             controller medications) approved by the child's regular doctor&#xD;
&#xD;
          -  Parental consent and child's assent to participate in the study.&#xD;
&#xD;
        Additional inclusion criteria applied after the run-in period, to be eligible for&#xD;
        randomization:&#xD;
&#xD;
          -  Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the&#xD;
             run-in period&#xD;
&#xD;
          -  Willingness to be randomized and complete study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum calcium &gt;10.8 mg/dl&#xD;
&#xD;
          -  Serum 25(OH) D &lt;14 ng/ml (35 nmol/L)&#xD;
&#xD;
          -  Chronic respiratory disorder other than asthma&#xD;
&#xD;
          -  Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in&#xD;
             previous year OR ≥6 severe asthma exacerbations in previous year)&#xD;
&#xD;
          -  Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect&#xD;
             vitamin D metabolism&#xD;
&#xD;
          -  Current smoking, or former smoking if ≥5 pack-years&#xD;
&#xD;
          -  Immune deficiency, cleft palate or Down's syndrome&#xD;
&#xD;
          -  Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3&#xD;
&#xD;
          -  Chronic oral corticosteroid therapy&#xD;
&#xD;
          -  Inability to perform acceptable spirometry&#xD;
&#xD;
          -  Use of investigational therapies or participation in trials 30 days before or during&#xD;
             the study&#xD;
&#xD;
          -  Participant is currently breast feeding an infant&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Weight less than 10 kg&#xD;
&#xD;
          -  Plans to move out of the study site area in the next year&#xD;
&#xD;
        Additional exclusion criteria applied after the run-in period:&#xD;
&#xD;
          -  Any severe asthma exacerbation during the run-in period&#xD;
&#xD;
          -  Need for asthma medications other than ICS and p.r.n. rescue inhalers during the&#xD;
             run-in period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C. Celedón, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Wisniewski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>October 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2020</results_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Juan Celedon, MD</investigator_full_name>
    <investigator_title>Niels K. Jerne Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Vitamin D, severe asthma exacerbations, children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02687815/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 595 participants assessed for eligibility, 192 finished run-in and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3</title>
          <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3</title>
          <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="2.5"/>
                    <measurement group_id="B2" value="9.7" spread="2.5"/>
                    <measurement group_id="B3" value="9.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race abd ethnicity were ascertained per parental report. &quot;Other race&quot; includes American Indian, Alaskan Native, mixed, and other reported as &quot;other&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other Race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parental Education</title>
          <population>2 participants from the Vitamin D3 group and 1 participant from the placebo group did not have information on parental education</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>High school or less</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Completed college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postgraduate education</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Household smoke exposure before age 2 years</title>
          <population>2 participants from Vitamin D3 group and 2 participants from Placebo gorup did not have information on household smoke expousre before age 2 years</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                    <count group_id="B2" value="94"/>
                    <count group_id="B3" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current household smoke exposure</title>
          <population>3 participants from Vitamin D3 group and 3 participants from Placebo group did not have information on household smoke exposure during the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="93"/>
                    <count group_id="B2" value="93"/>
                    <count group_id="B3" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Season of enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>January-March</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>April-June</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>July-September</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>October-December</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test score &gt;19</title>
          <description>The Asthma Control Test (ACT) was administered to participants aged 12 years or older, and the Childhood Asthma Control Test (C-ACT) was administered to participants aged 6 to 11 years. The ACT is calculated based on 5 self-administered questions and has a score ranges of 5 to 25. The C-ACT is calculated based on 7 questions (3 answered by the parent and 4 answered with the child's input) and has a score range of 0 to 27. For both, a higher score indicates better symptom control, and a score greater than 19 indicates well-controlled asthma symptoms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index z-score</title>
          <description>A body mass index z-score is a measure of relative weight adjusted for the child's age and sex. BMI z-scores were calculated using US Centers for Disease Control and Prevention (CDC) equations that create z-scores and percentiles for a child's sex and age. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.</description>
          <population>1 participant in the Vitamin D3 group did not have a valid BMI z-score</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="1.1"/>
                    <measurement group_id="B2" value="0.9" spread="1.3"/>
                    <measurement group_id="B3" value="0.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>No. of severe exacerbations in the previous year</title>
          <description>A severe asthma exacerbation was defined as the occurrence of either (1) use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or (2) a hospitalization or ED visit because of asthma, requiring systemic corticosteroids</description>
          <population>8 participants in the Vitamin D3 group and 10 participants in the placebo group did not have such information</population>
          <units>exacerbations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="4.6"/>
                    <measurement group_id="B2" value="22.8" spread="4.6"/>
                    <measurement group_id="B3" value="22.6" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1</title>
          <description>Forced Expiratory Volume in the first second (FEV1) refers to the maximum amount of air that the subject can forcibly expel during the first-second following maximal inhalation. All participants performed spirometry following American Thoracic Society/European Respiratory Society guidelines. Calculated using reference values from the third National Health and Nutrition Examination Survey. Values 80% of predicted or greater are considered normal.</description>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.9" spread="15.8"/>
                    <measurement group_id="B2" value="90.6" spread="17.3"/>
                    <measurement group_id="B3" value="92.2" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC</title>
          <description>FEV1/FVC is the ratio of the forced expiratory volume in the first one second (FEV1) to the forced vital capacity (FVC, the total amount of air exhaled) of the lungs. A reduced FEV1/FVC represents obstruction of airflow. All participants performed spirometry following American Thoracic Society/European Respiratory Society guidelines. Calculated using reference values from the third National Health and Nutrition Examination Survey. Values 80% of predicted or greater are considered normal.</description>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.5" spread="9.3"/>
                    <measurement group_id="B2" value="89.6" spread="10.1"/>
                    <measurement group_id="B3" value="90.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Control Test score</title>
          <description>For participants aged ≥12 years, asthma control was assessed using the Asthma Control Test (ACT [score range, 5-25].&#xD;
For participants aged &lt;12 (6-11) years, asthma control was assessed using Childhood ACT (C-ACT [score range,0-27].&#xD;
For both tests, higher scores mean better symptom control, and more than 19 points is considered well controlled asthma.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="96"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="3.2"/>
                    <measurement group_id="B2" value="21.3" spread="3.6"/>
                    <measurement group_id="B3" value="21.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days to a Severe Asthma Exacerbation</title>
        <description>A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.</description>
        <time_frame>48 weeks</time_frame>
        <population>Intent to treat population across the 48-week study period</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to a Severe Asthma Exacerbation</title>
          <description>A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.</description>
          <population>Intent to treat population across the 48-week study period</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="105.8"/>
                    <measurement group_id="O2" value="253" spread="101.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Viral-induced Severe Exacerbation</title>
        <description>A severe viral asthma exacerbation is defined as a severe asthma exacerbation [defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids] along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.</description>
        <time_frame>48 weeks</time_frame>
        <population>In Vitamin D3 gorup, 82 with time to viral exacerbation were included in the analysis (14 first exacerbations not tested). In Placebo group, 83 with time to viral exacerbation were included in the analysis (13 first exacerbations not tested)</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Viral-induced Severe Exacerbation</title>
          <description>A severe viral asthma exacerbation is defined as a severe asthma exacerbation [defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR 2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids] along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.</description>
          <population>In Vitamin D3 gorup, 82 with time to viral exacerbation were included in the analysis (14 first exacerbations not tested). In Placebo group, 83 with time to viral exacerbation were included in the analysis (13 first exacerbations not tested)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272" spread="87.8"/>
                    <measurement group_id="O2" value="281" spread="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants in Whom Fluticasone Dose Was Halved at Visit 6</title>
        <description>In the absence of moderate or severe asthma exacerbations, participants may have their dose of inhaled corticosteroids (ICS) reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):&#xD;
Asthma Control Test (ACT) score greater than 19&#xD;
Both pre-bronchodilator FEV1 and FEV1/FVC ≥80% of predicted&#xD;
Use of ≤4 puffs of a rescue inhaler per week&#xD;
≤1 day per month with asthma symptoms preventing full participation in usual daily activities&#xD;
Clinician's judgment regarding adequate asthma control</description>
        <time_frame>24 weeks</time_frame>
        <population>In the Vitamin D3 group, 91 subjects with data on reduction in the dose of inhaled corticosteroids (4 withdrew before 24 wk, 1 missed 24-wk visit). In the Placebo group, 91 subjects had data on reduction in the dose of inhaled corticosteroids (4 withdrew before 24 wk, 1 missed 24-wk visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants in Whom Fluticasone Dose Was Halved at Visit 6</title>
          <description>In the absence of moderate or severe asthma exacerbations, participants may have their dose of inhaled corticosteroids (ICS) reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):&#xD;
Asthma Control Test (ACT) score greater than 19&#xD;
Both pre-bronchodilator FEV1 and FEV1/FVC ≥80% of predicted&#xD;
Use of ≤4 puffs of a rescue inhaler per week&#xD;
≤1 day per month with asthma symptoms preventing full participation in usual daily activities&#xD;
Clinician's judgment regarding adequate asthma control</description>
          <population>In the Vitamin D3 group, 91 subjects with data on reduction in the dose of inhaled corticosteroids (4 withdrew before 24 wk, 1 missed 24-wk visit). In the Placebo group, 91 subjects had data on reduction in the dose of inhaled corticosteroids (4 withdrew before 24 wk, 1 missed 24-wk visit)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Cumulative Prescribed Dose of ICS at the End of the Trial</title>
        <description>The average cumulative dose of inhaled corticosteroids (ICS) during the study period</description>
        <time_frame>48 weeks</time_frame>
        <population>Intent to treat population across the 48-week study period</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Cumulative Prescribed Dose of ICS at the End of the Trial</title>
          <description>The average cumulative dose of inhaled corticosteroids (ICS) during the study period</description>
          <population>Intent to treat population across the 48-week study period</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="22.9"/>
                    <measurement group_id="O2" value="55.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>8.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>A hospitalization for an asthma exacerbation was considered a serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3</title>
          <description>Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily&#xD;
vitamin D3 4000 IU: The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo formulations will be in gel cap form and identical to the active drug&#xD;
Placebo: The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>severe neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for asthma exacerbation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pneumonia/otitis/hives</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractures</sub_title>
                <description>Fractures</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited statistical power to determine if vitamin D supplementation prolongs the time to a severe asthma exacerbation in children with vitamin D level &lt;20 ng/ml.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Juan Celedón</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>(412) 692-8429</phone>
      <email>juan.celedon@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

